US Stock MarketDetailed Quotes

ENOV Enovis Corp

Watchlist
  • 42.100
  • -1.430-3.29%
Close Feb 25 16:00 ET
  • 43.000
  • +0.900+2.14%
Pre 07:33 ET
2.39BMarket Cap-19.40P/E (TTM)

About Enovis Corp Company

Enovis Corp. operates as a medical technology growth company. It develops clinically differentiated solutions that generate measurably better patient outcomes and transform workflows. The firm operates through the following segments: Prevention & Recovery and Reconstructive. The Prevention & Recovery segment provides orthopedic and recovery science solutions, including devices, software, and services across the patient care continuum from injury prevention to rehabilitation after surgery, injury, or from degenerative disease. The Reconstructive segment provides surgical implant solutions, offering a comprehensive suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger and surgical productivity tools. The company was founded by Mitchell P. Rales and Steven M. Rales in 1995 and is headquartered in Wilmington, DE.

Company Profile

SymbolENOV
Company NameEnovis Corp
Listing DateMay 8, 2008
Founded1995
CEOMr. Matthew L. Trerotola
MarketNYSE
Employees6550
Fiscal Year Ends12-31
Address2711 Centerville Road,Suite 400
CityWilmington
ProvinceDelaware
CountryUnited States of America
Zip Code19808
Phone1-302-252-9160

Company Executives

  • Name
  • Position
  • Salary
  • Matthew L. Trerotola
  • Chairman of the Board and Chief Executive Officer
  • 10.77M
  • Brady R. Shirley
  • President, Chief Operating Officer and Director
  • 5.20M
  • John Kleckner
  • Vice President, Controller and Chief Accounting Officer
  • --
  • Phillip Benjamin Berry
  • Senior Vice President and Chief Financial Officer
  • 2.36M
  • Patricia A. Lang
  • Senior Vice President and Chief Human Resources Officer
  • 2.07M
  • Daniel A. Pryor
  • Executive Vice President, Strategy and Business Development
  • 4.75M
  • Bradley J. Tandy
  • Senior Vice President and General Counsel
  • --
  • Terry D. Ross
  • Group President, Prevention and Recovery
  • --
  • Louie Vogt
  • Group President, Reconstructive
  • --
  • A. Clayton Perfall
  • Independent Director
  • 308.93K
  • Liam J. Kelly
  • Independent Director
  • 283.93K
  • Dr. Christine Ortiz, B.S.,M.S.,PhD
  • Independent Director
  • 283.93K
  • Philip A. Okala
  • Independent Director
  • 283.93K
  • Rajiv Vinnakota
  • Independent Director
  • 298.93K
  • Sharon L. Wienbar
  • Lead Independent Director
  • 316.46K
  • Barbara W. Bodem
  • Independent Director
  • 283.93K
  • Angela S. Lalor
  • Independent Director
  • 296.46K

Trending Stocks

Reassessing Chinese Assets
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.
Discussing
FOMC leaves rates unchanged, how will you adjust your portfolio?
FOMC left the target Federal Funds rate unchanged at at target of 4.25%-4.5%, how will you adjust your portfolio? Show More